SCHEMBL20570798

SCHEMBL20570798

COC(=O)C1(Oc2cc(Cl)ccc2C=O)CC1

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 4/20 0.39
TDP1 Q9NUW8 1/20 0.39
SRC P12931 1/20 0.37
ALDH1A1 P00352 4/20 0.36
HPGD P15428 2/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
POLA1 P09884 2/20 0.35
GLA P06280 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ABL1 P00519 1/20 0.33
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2428471 0.85 ERN1 (0.40) ERN1ALDH1A1HPGDPOLA1MEN1
SCHEMBL20151862 0.85 ERN1 (0.38) ERN1SRCALDH1A1HPGDLMNA
SCHEMBL20570936 0.85 TDP1 (0.42) ERN1TDP1SRCALDH1A1HPGD
SCHEMBL20137021 0.81 KDM4E (0.39) ALDH1A1HPGDMEN1KMT2A
SCHEMBL20182572 0.80 ALDH1A1 (0.43) ERN1SRCALDH1A1HPGDLMNA
SCHEMBL696193 0.73 HPGD (0.43) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL1570210 0.72 ALDH1A1 (0.63) ERN1TDP1SRCALDH1A1HPGD
SCHEMBL16766994 0.72 ERN1 (0.42) ERN1TDP1ALDH1A1HPGDSMN1; SMN2
SCHEMBL32675256 0.71 SOD1 (0.41) SMN1; SMN2MEN1KMT2A
SCHEMBL26126678 0.71 HPGD (0.40) ALDH1A1HPGDLMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3634404-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2024-11-20 EP disclosed
CN-110678177-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-06-13 CN disclosed
US-11149037-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2021-10-19 US disclosed
US-11149037-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2021-10-19 US disclosed
EP-3634404-A1 PYRAZOLE MAGL INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2020-04-15 EP disclosed
US-20200087304-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2020-03-19 US disclosed
US-20200087304-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2020-03-19 US disclosed
CN-110678177-A Pyrazole MAGL inhibitors 隆德贝克拉荷亚研究中心有限公司 2020-01-10 CN disclosed
WO-2018217809-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11149037-B2 Pyrazole MAGL inhibitors MAGI3, MAG, PYM1 ERN1 1636/4885TDP1 2685/4885SRC 3299/4885
US-20200087304-A1 PYRAZOLE MAGL INHIBITORS MAGI3, MAG, PYM1 ERN1 1636/4885TDP1 2685/4885SRC 3299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.